We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

By LabMedica International staff writers
Posted on 24 Nov 2025

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. More...

Despite TB infecting 10 million people yearly, the immune mechanisms driving EPTB have remained unclear. A new study now maps the disease’s molecular activity in blood, identifying immune patterns that could lead to targeted therapies and non-invasive diagnostic tests.

In the collaborative study, researchers at the German Center for Infection Research (DZIF), Braunschweig, Germany) used blood samples from EPTB patients for applying multi-omics profiling, including single-cell RNA sequencing, to chart how immune cells communicate during infection.

The approach revealed complex signaling networks involving interferon and interleukin-1 pathways, as well as activation patterns of T cells and natural killer cells. Based on these molecular interactions, researchers identified three distinct “immunotypes,” each representing a unique disease course. The findings, published in Nature Communications, show that these immunotypes expose new biological mechanisms that shape how EPTB develops and progresses.

In addition to immune profiling, the team constructed gene expression–based biomarkers that accurately differentiated extrapulmonary from pulmonary TB. Current diagnosis of EPTB often requires invasive tissue biopsy; however, the newly identified blood signatures could serve as a future non-invasive diagnostic tool. These markers may help clinicians detect EPTB earlier, classify disease severity, and tailor treatments more precisely.

The investigators emphasize that integrating clinical data was essential to correctly interpret molecular findings and connect them to real patient outcomes. Their blood-based biomarker panel is now being validated in the larger mEX-TB clinical study, marking a step towards translation into clinical practice.

"These findings have the potential to substantially advance the diagnosis and treatment of tuberculosis and to facilitate the development of targeted, personalized therapies," said Dr. Thomas Ulas, a bioinformatician at the DZNE.

Related Links:
DZIF


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Electrolyte Analyzer
BKE-B
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Molecular Diagnostics

view channel
Image: Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC joins the Cologuard Plus test in Abbott’s screening portfolio, which now spans both stool‑ and blood‑based options (Photo courtesy of Freenome)

Blood-Based Test Broadens Colorectal Cancer Screening Options

Colorectal cancer is the second-leading cause of cancer-related death in the U.S., yet outcomes improve markedly when the disease is detected through routine screening. Despite this, up to 60 million Americans... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.